Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Rain Therapeutics Announces a Poster Presentation at the 2022 San Antonio Breast Cancer Symposium | ||||||||||||||
By: GlobeNewswire - 23 Nov 2022 | Back to overview list |
|||||||||||||
NEWARK, Calif., Nov. 23, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (Rain), a late-stage biotechnology company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced a poster presentation at the upcoming 2022 San Antonio Breast Cancer Symposium (SABCS) taking place on December 6-10, 2022 in San Antonio, TX.
A copy of the presentation materials can be accessed by visiting the "Resources” section of the Rain website after the conclusion of the presentation and will be archived on the Rain website. About Rain Therapeutics Inc. Investor Contact Media Contact |
||||||||||||||
|
||||||||||||||
Copyright 2022 GlobeNewswire | Back to overview list |